Archives | the Map Newsletter
3 posts published by ISMPP_MAP during October 2025| the Map Newsletter
3 posts published by ISMPP_MAP during October 2025| the Map Newsletter
You are a medical publication professional in a pharmaceutical company, working on a clinical trial publication for a novel drug that has the potential to revolutionize the treatment of a life-threatening disease. Some of the authors are keen to emphasize the promising efficacy outcomes without, in your opinion, incorporating the same level of detail about certain adverse events. What Would You Do?| the Map Newsletter
In today’s data-rich environment, the life sciences sector continues to struggle with a surprisingly persistent challenge: inconsistent communication of evidence across stakeholder audiences. A practical way forward is the alignment of Integrated Evidence Generation Plans (IEGPs) with strategic publication planning. This article explores how medical communications and publications professionals can help create stronger, more coordinated scientific communication by connecting the "what" (evi...| the Map Newsletter
The Request for Information (RFI) and Request for Proposal (RFP) processes are critical components of medical publication management, enabling stakeholders to evaluate services and establish strate…| the Map Newsletter
ISMPP is proud to announce that an article on its journey of engagement with patients as partners in medical publications was published on September 9, 2025 in Current Medical Research and Opinion …| the Map Newsletter
Predatory journals and congresses represent a significant and growing threat to the integrity of medical research, publishing, and scientific dissemination. Raising awareness across all scientific and medical communities, not just among those in publishing, is therefore crucial. This article provides practical guidance, particularly on how to identify and avoid predatory journals and congresses.| the Map Newsletter
Artificial Intelligence (AI) is rapidly transforming the way we approach medical communications, but how are ISMPP members really using AI today? Where is AI helping the most, what barriers remain,…| the Map Newsletter
You are a medical publication professional in a pharmaceutical company, working on a clinical trial publication for a novel drug that has the potential to revolutionize the treatment of a life-threatening disease. Some of the authors are keen to emphasize the promising efficacy outcomes without, in your opinion, incorporating the same level of detail about certain adverse events. What Would You Do?| the Map Newsletter
Healthcare information has never been more readily available than it is now. However, accessibility goes beyond mere access to information; it encompasses ensuring that all individuals—regardless of physical, sensory, or cognitive ability—can access, understand, and benefit from healthcare content. This article discusses the benefits of accessible healthcare content, current accessibility standards, common barriers, and practical tools and strategies to enhance accessibility.| the Map Newsletter
Medical communications professionals within pharmaceutical companies and agencies are navigating the rapid acceleration of technological advances, particularly the implications and uptake of genera…| the Map Newsletter
The publication team is eager to submit an abstract to a prestigious congress, but you face a dilemma. The congress explicitly states that it accepts original content only, whereas the publication team wants to develop an abstract based on data from three previously shared abstracts/publications. As the publication lead, you need to decide on the best course of action. What would you do?| the Map Newsletter
